Ernexa Therapeutics Inc.
ERNA
$0.207
-$0.001-0.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.40% | -375.84% | -22.65% | -22.73% | -37.07% |
| Total Depreciation and Amortization | -85.86% | -12.77% | 817.46% | 772.58% | 459.30% |
| Total Amortization of Deferred Charges | 1,139.44% | 2,263.46% | -- | -- | -- |
| Total Other Non-Cash Items | 57.88% | 8,109.74% | -23.23% | 18.98% | 142.38% |
| Change in Net Operating Assets | -404.70% | -206.35% | 5,252.94% | 166.22% | 236.44% |
| Cash from Operations | 23.94% | -7.88% | 41.66% | 38.06% | 14.24% |
| Capital Expenditure | 100.00% | -- | -- | -- | 9.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | -114.73% |
| Total Debt Issued | -100.00% | -55.40% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -149,900.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 0.00% | -- | 0.00% |
| Other Financing Activities | -77.63% | 100.00% | -- | -- | 31.53% |
| Cash from Financing | -86.89% | -54.48% | -107.05% | -- | 1.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -183.83% | -189.06% | 28.93% | 59.35% | 32.23% |